Research News

• Brenipatide Phase 3: GLP-1 and Addiction

  Brenipatide's Phase 1 data is early, conference-grade. Phase 3 alcohol and depression trials are running but not read out; no addiction use is approved.

  Sep 19, 2026

• Semaglutide and Asthma: What the ERS 2026 Study Found

  A UK records study presented at the ERS Congress found semaglutide associated with fewer asthma attacks and COPD flare-ups. Observational, not peer-reviewed.

  Sep 18, 2026

• Anthropic's LSVP Opens Mythos 5.1 to Peptide R&D Teams

  Anthropic's Life Sciences Verification Program gives vetted labs Mythos 5.1 with biology safeguards dialled back. What peptide R&D teams must prove.

  Sep 17, 2026

• Elvinix Licenses Zealand GLP-1/Gastrin Peptide for Type 1 Diabetes

  Elvinix acquires Zealand Pharma's GLP-1/gastrin dual-agonist peptide platform to advance a disease-modifying beta-cell regenerative therapy for T1D.

  Sep 16, 2026

• Can Ozempic Cause Wernicke Encephalopathy? 15 Cases

  The evidence does not show GLP-1 medicines caused these 15 Wernicke cases. A Clinical Nutrition review found the thiamine deficiency behind them.

  Sep 14, 2026

• Gray Market Peptides 2026: What 9,997 Lab Tests Found in the Vials

  Finnrick's 9,997 peptide lab tests: about one in three fail quality checks. What the numbers cover, what they miss, and how regulators verify vials.

  Sep 13, 2026

• Semaglutide Discontinuation Rates 2026: Who Stops and What's Next

  Danish registry data show 49% of semaglutide users stopped within a year. A 2026 model projects 1.04 kg/month regain after stopping. What the numbers mean.

  Sep 11, 2026

• GLP-1 Pill vs Injection: Oral vs Injectable Semaglutide

  GLP-1 pill vs injection: oral and injectable Wegovy carry the same molecule but differ on dosing, food rules, refrigeration and price. How they compare.

  Sep 10, 2026

• Online Retatrutide: Type 1 Diabetes Case

  Case report: a man with type 1 diabetes hospitalized after an online-sourced product marketed as retatrutide; infection confounded it.

  Sep 9, 2026

• Peptide TT-P34 Passes Phase 1 Trial in Early Parkinson's Disease

  Teitur Trophics says its neuroprotective peptide TT-P34 was safe at all doses in 67 volunteers and patients and reached the brain. Phase 2 is planned for 2027.

  Sep 9, 2026

• Copper Peptide Injections: GHK-Cu Trend Outruns the Science

  Copper peptide injections are spreading on social media with thin human safety data behind them. Dermatologists urge caution as FDA weighs a 2027 GHK-Cu review.

  Sep 6, 2026

• Peptides and Cancer: MSK Oncologist on Unanswered Questions

  MSK oncologist Dr. Larry Norton: wellness peptides' effects on cancer cells are unknown; evidence is thin, and compounding access is not FDA approval.

  Sep 3, 2026

• Ozempic Hair Loss: 2026 NYU & Penn Studies

  Do Ozempic and semaglutide cause hair loss? NYU's 2026 genetic study found a 7% added risk in prone men; Penn found low absolute risk. What to know.

  Sep 2, 2026

• Semaglutide Lifespan Mouse Study: What Nature Found

  Nature study: semaglutide extended lifespan in older female mice and slowed aging hallmarks. Here's the evidence, the limits, and why it isn't human proof yet.

  Sep 2, 2026

• UCLA Health reviewed 6 peptides: the evidence

  UCLA Health reviewed six popular peptide supplements — BPC-157, TB-500, CJC-1295, MK-677, ipamorelin, GHK-Cu. Little evidence; verdict: cannot be recommended.

  Sep 2, 2026

• Semaglutide Bipolar Disorder: The 21% Hospitalization Signal

  Semaglutide bipolar disorder: a Swedish study found 21% fewer psychiatric hospitalizations, but it's not proof and not medical advice.

  Aug 29, 2026

• Do Peptides Work for Looksmaxxing? Science vs. Hype

  Looksmaxxing peptides are the internet's newest shortcut — but the evidence doesn't back the hype. What researchers and doctors say about BPC-157 and GHK-Cu.

  Aug 23, 2026

• Aleniglipron: The New Oral GLP-1 Pill With 12.1% Weight Loss at 36 Weeks

  Aleniglipron (GSBR-1290) delivered 12.1% weight loss at 36 weeks in the Phase 2b ACCESS trial. Is it FDA approved? Compare it to the Wegovy pill and Foundayo.

  Aug 23, 2026

• Oral GLP-1 Comparison 2026: Aleniglipron vs Wegovy Pill vs Foundayo

  Oral GLP-1 pills compared: aleniglipron 12.1% at 36 weeks, Wegovy pill, Foundayo, Rybelsus, elecoglipron — efficacy, dosing, food rules, FDA status.

  Aug 23, 2026

• What Is TOFA? Fat Loss Without Muscle Loss (2026)

  TOFA burned fat without muscle loss in a new Science Advances mouse study — and boosted GLP-1 results. Here's what the 2026 evidence actually shows.

  Aug 23, 2026

• How Many People Use BPC-157? The 2026 Numbers

  1,039 clinician-documented BPC-157 users in a 15.2-million-record network, and a 33-fold rise since 2020 — the 2026 data, sourced to Reuters (Sept 15, 2026).

  Aug 22, 2026

• Does GLP-1 Reduce Belly Fat? 2026 Evidence on Visceral Fat

  Does GLP-1 reduce belly fat? We break down the 2026 trial data on visceral fat loss, waist reduction, and heart-health benefits, with realistic timelines.

  Aug 15, 2026

• Peptides, Explained: What the Science Says vs. What the Hype Claims

  Peptides are the hottest wellness trend — but what does the science actually say? Stanford experts on BRP, the evidence gap, and what's FDA-approved.

  Aug 11, 2026

• AI Designs Better Peptide Antibiotics in Landmark UPenn Study

  ApexGO, a new Penn AI system, designed antibiotic peptides that halted 85% of bacterial growth in lab tests and outperformed existing candidates.

  May 13, 2026

• PubMed Digest — May 2026: BPC-157, MOTS-c, LL-37 Research Updates

  Recent peer-reviewed publications on BPC-157, MOTS-c, GHK-Cu, Epitalon, and LL-37 — systematic reviews, mechanistic studies, and antimicrobial advances.

  May 7, 2026

• BPC-157: What the Research Actually Shows (And What It Doesn't)

  BPC-157 has the strongest practitioner reputation of the reclassified peptides. An honest read on preclinical breadth, human trial gaps, and what it means.

  Apr 27, 2026